Lead sponsor
Regeneron Pharmaceuticals
4 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
4
Trials led
4
Ongoing
1,689
Total enrollment
67
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
4
Trials by status
Not yet recruiting
1
Recruiting
2
Active, not recruiting
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesBMI 30-45Ph 2Not yet recruiting360
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDBMI 30-45Ph 2Recruiting204
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USBMI 27-45Ph 2Recruiting120